Kezar Life Sciences gets $50 million credit facility via Oxford

By Marisa Wong

Los Angeles, Nov. 10 – Kezar Life Sciences, Inc. obtained a $50 million senior secured term loan through Oxford Finance LLC, according to a press release.

Proceeds from the transaction will be used for general growth capital and for further advancement of Kezar’s clinical candidates, KZR-616 and KZR-261.

Kezar is a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders. The company is based in South San Francisco, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.